Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 約 35 days | ¥ 18,000 |
5 mg | 約 35 days | ¥ 63,000 |
10 mg | 約 35 days | ¥ 105,500 |
25 mg | 約 35 days | ¥ 197,000 |
In vitro | In a Swiss albino mouse model loaded with Dalton's lymphoma, intraperitoneal injection of SCR7 (20 mg/kg) fails to reduce tumor size. Conversely, in BALB/c mice, intraperitoneal injection of SCR7 (20 mg/kg) enhances the cytotoxic effects of radiation, etoposide, and 3-aminobenzamide on derived tumors of Dalton's lymphoma cells. |
In vivo | SCR7 exhibits significant inhibition of cell proliferation across various cell lines, with IC50 values reported as follows: 40 μM in MCF7 cells, 34 μM in A549 cells, 44 μM in HeLa cells, 8.5 μM in T47D cells, 120 μM in A2780 cells, 10 μM in HT1080 cells, and 50 μM in Nalm6 cells. |
分子量 | 334.4 |
分子式 | C18H14N4OS |
CAS No. | 1533426-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (134.57 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SCR7 1533426-72-0 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis CRISPR/Cas9 gene end-joining nonhomologous SCR 7 Caspase 9 phosphorylation Caspase 3 ligase-IV SCR-7 inhibit replacement Inhibitor DNA anticancer inhibitor